Tumour lysis syndrome: new therapeutic strategies and classification.
about
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancerUrate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancerThe tumor lysis syndromeRasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in goutRisk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) projectRecognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignanciesPrevention and management of tumor lysis syndrome in adults with malignancyA focused review of the pathogenesis, diagnosis, and management of tumor lysis syndrome for the interventional radiologistRasburicase in the management of tumor lysis: an evidence-based review of its place in therapyA review in the treatment of oncologic emergencies.Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in Lymphoblastic Leukemia.Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.Complications of "very high" leukocytosis in pediatric acute leukemia patients managed without rasburicase and leukopheresis.Carfilzomib-associated tumor lysis syndrome.Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries.Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.Tumor lysis syndrome: new challenges and recent advances.The utility of online haemodiafiltration in methotrexate poisoning.Spontaneous tumor lysis syndrome in the setting of B-cell lymphoma.Tumor Lysis Syndrome in Solid Tumors: An up to Date Review of the LiteratureA randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndromeOncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment.A tumour lysis syndrome in a chemotherapy naïve patient with metastatic pancreatic adenocarcinomaTumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literatureUric acid and the prediction models of tumor lysis syndrome in AMLHyperuricemia and acute kidney injury secondary to spontaneous tumor lysis syndrome in low risk myelodysplastic syndrome.Emerging role of rasburicase in the management of increased plasma uric acid levels in patients with hematologic malignancies.Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experienceTumor Lysis Syndrome in a Retroperitoneal Sarcoma.Hyperuricemic renal failure in nonhematologic solid tumors: a case report and review of the literature.Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.Rasburicase-Induced Methemoglobinemia in a Patient with Aggressive Non-Hodgkin's Lymphoma.Diagnostic pitfalls of discriminating lymphoma-associated effusions.Outcomes in Critically Ill Patients with Cancer-Related ComplicationsContinuing challenges in childhood non-Hodgkin's lymphoma.Bendamustine for treatment of chronic lymphocytic leukemia
P2860
Q24194387-7FF42A78-A7E2-4481-B298-AEECDB038F39Q24234902-9444335D-74C1-402F-84B5-CEB9A32AE9C9Q24605151-D399C246-DB2D-4A8F-BDEA-2E1FB60E0DA1Q24673444-DFE91F54-91EF-4241-AA56-734E7D08A4BBQ26822723-BCEC6009-154A-4952-9FC5-B03882EAE3ABQ26862904-E2F7F63E-0E4A-40F5-B4F5-48EBFEC924DAQ27003152-7C97E0BE-DF10-4358-BA5A-9397BCD63036Q27012513-D8B7AF76-60FF-446B-A582-5B28E538840AQ28082089-9D1A1CDA-B215-4C12-BD38-922C895E97FAQ30252082-A03D0A6C-FBCE-40DA-B6B8-DFCB1B126AE6Q30279207-2A545DF3-A4BE-497D-80CD-B598832AEDC1Q30358639-7094935C-16DD-410A-BAA3-4A6C5DD21DEDQ30363892-1A9C6E7E-8BE5-43C2-A0D3-DAE70322E41AQ33396918-D1A415D3-C537-416E-A355-9FB4EE57C923Q33410630-357F1081-A1D2-456D-A127-3AE3258296E7Q33412480-17FEBB6A-B87E-4ED4-92A8-A088FBD2A32EQ33423131-AEF5D660-63C1-443B-AEAC-C6661AB754BFQ33429161-41DADF5A-FDED-468E-AD22-949B3F2DA74DQ33438494-95434F50-D160-4620-B1C2-94CB0990E560Q33595615-6A5964C4-CD5C-455C-BD25-9BEF5C3DEEF5Q33691618-9C65009A-26DD-493E-817D-646DFDC4F157Q33719237-B3EB0310-2603-4FB8-9BED-75A87A604CBBQ33852544-FD4840DD-3016-447C-89B2-4B424C92F183Q33947841-C580D5CE-5FD8-4D40-ACFF-FA2FC244C615Q34141630-426182E3-02C2-4726-BF71-3101D4CF5712Q34631769-64076C8D-F59A-44B6-B3E8-695EC6F6A8A4Q35065501-1CD5417B-9D5F-4AF7-8183-CF9F35841682Q35136271-72AB0557-3064-47DA-929E-1983F3727738Q35181858-136049CC-A7C9-42D1-B39D-32A2658EF50CQ35322376-D0B4E9EE-6A1C-4339-ABCC-D101A2D43F21Q35683889-5792BC5B-F17D-4E93-8F59-836AFEC68702Q35742173-33651E58-9077-45A2-8C2B-2DF2A0C7236AQ35927686-4A9B695F-EADE-42D0-8F95-24135E11A957Q36011108-B7E61014-6956-4725-9162-3AD6689C1E96Q36019515-1CC4B5D7-BC69-4DD9-82FA-16AF8B49A3C7Q36036576-037686BA-1452-46C2-B8AB-C24BA49758F6Q36153762-FD764AFD-290A-40F2-A9F7-9C603ED4904AQ36169137-8D85D237-01E6-45E5-A08E-932132178A8BQ36228057-9AD78358-4D0E-4E7A-B3C0-389F2CD9FD06Q36305762-BDEB5CBD-E8BE-49DA-8DF3-1FC154AB6500
P2860
Tumour lysis syndrome: new therapeutic strategies and classification.
description
2004 nî lūn-bûn
@nan
2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Tumour lysis syndrome: new therapeutic strategies and classification.
@ast
Tumour lysis syndrome: new therapeutic strategies and classification.
@en
type
label
Tumour lysis syndrome: new therapeutic strategies and classification.
@ast
Tumour lysis syndrome: new therapeutic strategies and classification.
@en
prefLabel
Tumour lysis syndrome: new therapeutic strategies and classification.
@ast
Tumour lysis syndrome: new therapeutic strategies and classification.
@en
P2860
P1476
Tumour lysis syndrome: new therapeutic strategies and classification.
@en
P2093
Michael Bishop
Mitchell S Cairo
P2860
P356
10.1111/J.1365-2141.2004.05094.X
P407
P577
2004-10-01T00:00:00Z